Mindblown: a blog about philosophy.

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]

Telomir Pharmaceuticals, a biotech company specializing in novel treatments for inflammatory diseases, announced today its initial public offering (IPO) aiming to raise $14 million. The Baltimore-based company, which was established in 2021, is focusing on the development of TELOMIR-1, an innovative oral therapy targeting essential metals in human stem cells. The company’s lead compound, TELOMIR-1, […]